

Impact Report: Naloxone365 First Year Review

Drug related deaths due to opioid overdose can be prevented by administering naloxone, a life-saving medication that can reverse the effects of an opioid overdose. Naloxone365 is New Jersey's first-in-the-nation program providing 4mg intranasal spray naloxone for free and anonymously to anyone 14 years of age and older at no cost to pharmacies. Individuals do not need to show proof of insurance, identification, or a prescription to obtain naloxone. The program launched in January of 2023 as part of the state's ongoing efforts to reduce overdose deaths in New Jersey.


132,014 doses of naloxone, or 66,007 kits, were distributed throughout the state.

Month		# of Doses	
January*	1,820	July	13,278
February	11,476	August	13,660
March	14,642	September	10,332
April	14,820	October	8,552
May	12,310	November	8,392
June	13,310	December	9,422

*Pharmacy enrollment and program utilization were low during January as it was the start of the program.

Year 1 of Naloxone365

664 pharmacies registered to participate.



Suspected drug related deaths in New Jersey have declined over the past two years following the implementation of initiatives such as Naloxone365. From 2022 to 2023, the state experienced a decrease in drug related deaths of over 11 percent. Research has shown that the provision of naloxone contributes significantly to this reduction.

For more information on Naloxone365 and a full list of locations on where to obtain naloxone for free, anonymously, and without a prescription, please visit StopOverdoses.nj.gov.

During 2023, Naloxone365 experienced a decrease in utilization during colder months and during holidays.

